GP Pharm: Injectable Products for the Urology, Oncology, CNS and CVS Fields
GP Pharm, the pharmaceutical company of the Lipotec Group, specialises in developing drug delivery formulations for the urology, oncology, central nervous system (CNS) and cardiovascular (CVS) fields. GP Pharm is a specialist in R&D for drug delivery formulations, and can also manufacture and commercialise drug products.
GP Pharm is able to produce cytotoxics and hormonal drug products in drug delivery formulations for itself and also for third parties.
Manufacturing of sterile formulations for injection
GP Pharm carries out manufacturing of sterile formulations for injection. These include:
- Cytotoxic products
- High-potency products
- Drug delivery systems: microspheres and liposomes
Various types of packaging are available, including vials, ampoules and pre-filled syringes. Both liquid and freeze-dried formulations are available. GP Pharm fulfils the annex 13 requirements of the GMPs so that in addition to pilot batches, validation batches and industrial batches, the company is also authorised to produce clinical batches.
Microspheres for drug delivery
GP Pharm has experience in obtaining microspheres through different technologies such as double emulsion and coacervation. GP Pharm’s own developments include:
- Agonists LHRH (leuprolide, triptorelin)
- New active peptides
- Peptides somatropin release-inhibiting factor SRIF or GHIH (octreotide LAR, MAR, SAR and somatostatin)
- Other molecules (risperidone)
Liposomes for injection
GP Pharm’s liposomes for injection are suitable for encapsulating cytotoxic compounds to reduce toxicity or increase bioavailability. GP Pharm has expertise using different compositions of lipid components for liposome preparation: cationic, anionic and neutral (used separately or in different ratios). GP Pharm can also obtain liposomes throughout different sizing technologies such as microfluidification, extrusion and sonication.
GP Pharm is developing Sarcodoxome® (liposomal doxorubicin), and is also currently manufacturing Myocet for US company Cephalon.
Peptide-based hormonal products
GP Pharm is currently developing generic hormonal products based on peptides such as octreotide. Octreotide for injection is a pure generic formulation based on a proprietary buffer system. It is registered in different countries worldwide.
GP Pharm is also working on the pharmaceutical development of vasopressin analogs, considering injection and oral solutions as routes of administration.
Desmopressin syrup is a new oral liquid formulation for Desmopressin that is bioequivalent to other oral formulations but offers easier administration (particularly useful for children and the elderly).
Generic cytotoxics for injection
GP Pharm has started development of generic formulations of some well-known cytotoxics for injection, including production of pilot batches, stability data and CTD registration dossiers. GP Pharm is offering these formulations to countries where no patent protection exists. The formulations are:
Pharmaceutical licensing opportunities
GP Pharm is interested in expanding its commercial network worldwide and is actively looking for win-to-win partnerships with other companies in terms of in-out licensing. GP Pharm currently has available for licensing:
- Lutrate® (leuprolide one and three month microspheres)
- Octreotide (SAR, LAR, MAR)
- Desmopressin oral drops
- Sarcodoxome® (liposomal doxorubicin)
In June 2017, US-based biopharmaceutical company Pfizer began building a research and development (R&D) laboratory and office facility in Chesterfield, Missouri.
For the eighth consecutive year GP Pharm will be present at CPhI, the world's most important pharma event, from 25-27 October this year. This year the exhibition takes place in Frankfurt and will feature companies from more than 125 different countries from throughout the fine chemicals
GP Pharm Expands its Pharmaceutical Line Against Advanced Colorectal Cancer with Oxaliplatin and Irinotecan 300mg and 500mg
GP Pharm has started the commercialisation of Oxaliplatin and Irinotecan 300mg and 500mg, drugs to treat metastatic colorectal cancer. Oxaliplatin 50mg and 100mg is a stereoisomer in injectable dosage form that, as happens with other derivatives of platinum, acts on the DNA causing alky
Last January, GCC-DR (Gulf Central Committee for Drug Registration) granted a Registration Certificate of Manufacturing Site to GP Pharm. This certificate is valid for the next five years, allowing GP Pharm to manufacture drug products for the region. The GCC-DR certificate covers auth
PHOENIX Study Proposes Integration Measures Between the Financial World and Biotechnological Companies
CataloniaBIO has launched the PHOENIX Study to get the financial world's vision about the sector and the financial needs of biotech companies. The study was presented on 7 July at the majestic Golden Hall of the Chamber of Commerce, Industry and Navigation of Barcelona and had as its ma
GP Pharm Named as One of the Most Innovative Pharmaceutical Companies in Spain for the Second Consecutive Year
GP Pharm, a pioneer in the development of controlled drug release, has been granted for the second consecutive year, the rating of 'very good' in the Plan Proforma. The certification awarded by this Plan, promoted by the Ministries of Industry, Tourism and Trade, Health and Social Policy, and Sci
GP Pharm has successfully participated again in the 46th euroPLX edition that took place in Vienna, on 30 and 31 May 2011. The main objective of GP Pharm during the event was to announce its product range and new projects, in order to find new partners. The event allowed GP P
GP Pharm to Begin Phase III Clinical Trial of Lutrate® Three Months for the Treatment of Advanced Prostate Cancer
GP Pharm, a pioneer in the development of drug delivery systems, will start the phase III clinical trial of three months Lutrate®, a formulation of a quarterly dose of Leuprolide based on sustained-release injectable microspheres technology for the treatment of advanced prostate cancer.
GP Pharm took part in the BioPartnering North America 2011 (BPN) celebrated in Vancouver (Canada) from 28 February to 1 March. Over 800 delegates, from 500 companies and 27 countries, joined this event at the Vancouver Convention Centre. BPN is the premier life science partnering conf
GP Pharm is the pharmaceutical branch of the Lipotec Group, based in Barcelona, Spain. GP Pharm specialises in the research, development, production and marketing of injectable products within the urology, oncology, central nervous system and cardiovascular fields, some of them based in proprieta
The Spanish biotech company GP Pharm, which pioneers and develops controlled release systems for injection, has filed the Lutrate Depot® 1 month (Leuprolide acetate 3.75mg) dossier for marketing in Spain, Portugal, Italy, Greece and Germany. It is the first decentralised procedure filed by
Final reports for preclinical studies for GP Pharm’s Liposomal Doxorubicine Sarcodoxome® have been released. Those studies are related to one of the major safety improvements of GP Pharm’s formulation and were performed at department of human toxicology, faculty of health, medicine and life scien
In November GP Pharm has obtained in Spain the approval for the Octreotide as generic product in four different presentations. (50mg/mL, 100mg/mL and 500mg/mL in ampoules, and 200mg multidose vials). This product has been filed also in Portugal and other countries in Europe and Australia and at t
Last December 3rd and 4th 2007 GP Pharm participate at the event Euroregional meetings for Biotechnology and Healthcare taking place at Toulouse (France). During this event GP Pharm had the chance to make interesting contacts with either French or Spanish companies Bioregion Mediterrane